Mechanisms of action of low-dose IL-2 restoration therapies in SLE

André Ballesteros-Tato; Amber Papillion

doi:10.1016/j.coi.2019.07.003

Mechanisms of action of low-dose IL-2 restoration therapies in SLE

Curr Opin Immunol. 2019 Dec:61:39-45. doi: 10.1016/j.coi.2019.07.003. Epub 2019 Aug 23.

Authors

André Ballesteros-Tato¹, Amber Papillion²

Affiliations

¹ Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: andreballesterostato@uabmc.edu.
² Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.

PMID: 31450016
DOI: 10.1016/j.coi.2019.07.003

Abstract

Interleukin-2 (IL-2) shortage is a hallmark of Systemic Lupus Erythematosus (SLE). Importantly, clinical and preclinical studies demonstrate the potential clinical benefits of IL-2-based restoration therapies for the treatment of SLE. Here we discuss the immunological consequences of IL-2 deficiency in SLE patients and the mechanisms underlying the therapeutic effects of low-dose IL-2 regimens.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Disease Management
Disease Susceptibility / immunology
Genetic Predisposition to Disease
Humans
Immunologic Factors / administration & dosage*
Interleukin-2 / administration & dosage*
Lupus Erythematosus, Systemic / drug therapy*
Lupus Erythematosus, Systemic / etiology
Lupus Erythematosus, Systemic / metabolism
Receptors, Interleukin-2 / metabolism
Signal Transduction
T-Lymphocyte Subsets / drug effects
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / metabolism
T-Lymphocytes, Regulatory / immunology
T-Lymphocytes, Regulatory / metabolism

Substances

Immunologic Factors
Interleukin-2
Receptors, Interleukin-2

Grants and funding

R01 AI110480/AI/NIAID NIH HHS/United States